March 21, 2023

Business Group on Health, in conjunction with other employer plan sponsor and insurer stakeholders, continues to advocate to the Departments of Labor (DOL), Health and Human Services (HHS), and Treasury/Internal Revenue Service (IRS) for additional guidance and compliance relief to assist employer plan sponsors comply with the prescription drug data collection and health care spending reporting requirements (RxDC reporting requirements) enacted by the Consolidated Appropriations Act, 2021 (CAA ’21). Although the Departments provided some temporary relief for the initial RxDC submissions due in December 2022, the Business Group continues to advocate for further compliance support in advance of the next RxDC submission deadline of June 1, 2023. The Business Group and other signatories requested that the Departments continue allowing multiple data file submissions by multiple reporting entities, continue to provide good faith reporting relief, as well as provide additional technical system improvements to reduce the administrative burden on plan sponsors and reporting entities.

Business Group and Other Partners Advocate for RxDC Guidance

More Topics

Policy & Advocacy Pharmacy/Prescription Drugs